Critical Care

, 13:P314 | Cite as

Malignant Boutonneuse fever with multiple organ failure: a three-case series

  • B Oliveira
  • AP Lacerda
  • Z Costa e Silva
  • C França
Poster presentation


Tetracycline Vasculitis Antibiotic Therapy Respiratory Failure Haemolytic Anaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Rickettsia conorii infection, the agent of Boutonneuse fever, presents usually in a form considered benign, with serious complications in less than 10% of patients. Its mechanism of infection consists of vascular endothelial invasion by the microorganism and subsequent vasculitis and tissue necrosis. The process is usually localized or limited to the skin but can progress with malignant severe systemic involvement [1, 2].


A series of three cases of patients with multiple organ failure admitted to an ICU with confirmed diagnosis of Boutonneuse fever is presented (positive serology or tissue PCR).


Common to all the patients was the rapid development of the disease (average: 3 days) from the initial complaints of fever after a bite by an unidentified agent and development of generalized rash, and the diagnosis of multiple organ failure (average Simplified Acute Physiology Score II: 59; average Sequential Organ Failure Assessment score on admission: 12.6). All developed respiratory failure requiring invasive mechanical ventilation, haematological failure with haemolytic anaemia and acute renal failure suggestive of serious widespread vasculitis. One of the cases developed lethal refractory septic shock within 6 hours of admission. Tetracycline antibiotic therapy was started early in all patients, based on clinical and epidemiological data, since initial microbiological results were negative.


This series of cases illustrates the most severe form of Boutonneuse fever, usually associated with comorbidities such as diabetes, malignant disease, immunodeficiency or delay in the diagnosis and appropriate antibiotic therapy, which was not the case in these patients.


  1. 1.
    Aharonowitz G, Koton S, Segal S, et al.: Epidemiological characteristics of spotted fever in Israel over 26 years. Clin Infect Dis 1999, 29: 1321-1322. 10.1086/313432CrossRefGoogle Scholar
  2. 2.
    Anton E, Font B, Munoz T, et al.: Clinical and laboratory characteristics of 144 patients with mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 2003, 22: 126-128.Google Scholar

Copyright information

© Oliveira et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • B Oliveira
    • 1
  • AP Lacerda
    • 1
  • Z Costa e Silva
    • 1
  • C França
    • 1
  1. 1.Hospital de Santa Maria LisboaPortugal

Personalised recommendations